Paradigm of Antibody Therapeutics in Lung Cancer Treatment Market
Global Lung Cancer Antibodies Market, Drug Sales & Clinical Trials Insight 2028 Report Highlights:
- Lung Cancer Antibodies Market Global & Regional Outlook
- Global Lung Cancer Antibodies Market Opportunity > USD 10 Billion
- Global & Regional Sales Analysis On 11 Antibodies
- Lung Cancer Immune Checkpoint Inhibitors, Monoclonal Antibodies, Bispecific Antibodies Insight
- Pricing, Dosage, Patent Insight On Approved Lung Cancer Antibodies
- Comprehensive Insight On More Than 200 Lung Cancer Antibodies in Clinical Trials
- Lung Cancer Antibodies in Clinical Trials Insight By Phase, Company, Orphan Designation
The newest class of therapeutics of lung cancer is immunotherapy which aims to reawaken or reboot the immune systems to target the cancer cell. The cancer immunotherapy is highly selective for the cancer cells and can potentially be tailored in the form of personalized therapy. As of now, therapeutic antibodies including Ryberant, Avastin, Portrazza and Cyramza; and immune checkpoint inhibitors including Tcentriq, Libtayo, Opdivo, Ketruda, Yervoy and Imfinzi have been approved for the management of lung cancer. Since their approval, these drugs have shown high penetration rate in the global market owing to their high specificity for the lung cancer cells. Moreover, they are generally well-tolerated, without the typical myelosuppresion, nausea, and other toxicities associated with chemotherapy.
The promising response of therapeutic in combinational therapy has gained interest from large pharmaceutical giants. The key players in the market have entered into partnerships, collaboration, or joint ventures to analyze different combinations to enhance the efficacy of immune checkpoint inhibitors as combinational therapies. Recently in 2022, Elicio Therapeutics announced clinical trial collaboration with Regeneron to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo® (cemiplimab), in patients with KRAS-driven tumors. The combination therapy will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC). Moreover, AUM Biosciences has announced clinical trial and supply agreement 3with Roche. The collaboration will access the safety and tolerability of AUM001, highly selective MNK1/2 inhibitor in combination with Tecentriq in various solid tumors such as non-small cell lung cancer.
Several factors such as high cost of therapy, unpredictable efficacy and stringent regulatory guidelines will restrain the growth of lung cancer antibody market. However, the increasing initiatives by government as well as private institutions has led to the development of favorable reimbursement policies, which can effectively reduce the out-pocket cost of patients. In addition to this, the looming patent expiry of these drugs provide new opportunities for the development of biosimilars drugs, which are priced lower than the branded drugs thus increasing accessibility to patients. The patent of Keytruda and Tecentriq are expected to expire during forecast period, thus driving the growth of lung cancer antibody market.
As per our report findings, the global lung cancer antibody market will surpass US$ 10 Billion by 2028. In coming years, there will be increase in prevalence of lung cancer which is mainly attributed to increased smoking, tobacco consumption, rise in geriatric population and physical inactivity. This will ultimately increase the demand of novel targeted drugs in the management of lung cancer, thus driving the lung cancer immunotherapy market. In addition, rising investment by pharmaceutical giants in the market is also boosting the growth of market during the forecast period.
Regionally, US is expected to dominate the global market which is mainly due to large target population, increasing awareness, and rising smoking population. The regulatory body in US also provides several designations which aim to expedite the drug development process or provide substantial benefits to the pharmaceutical companies to actively invest in this sector. FDA has granted orphan drug designation to Serplulimab for treatment for patients with small cell lung cancer. The investigation drug is first dual monoclonal antibody combination therapy with the ability to target PD-L1- and VEGF-expressing tumors which is developed Shanghai Helnius Biotech. Apart from this, the market in China is also expected to grow with high CAGR rates owing to presence of domestically developed antibody therapeutics. For instance in 2021, the China NMPA has approved the potential best-in-class anti-PD-L1 monoclonal antibody Cejemly in combination with chemotherapy for the treatment of treatment-naïve patients with stage IV NSCLC.